Therapeutic considerations when treating HER2-positive metastatic breast cancer
CC O'Sullivan, KL Smith - Current breast cancer reports, 2014 - Springer
Despite advances in detection and treatment, metastatic breast cancer (MBC) remains the
second highest cause of cancer-related death for women in the United States. Human …
second highest cause of cancer-related death for women in the United States. Human …
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast …
The role of the dual HER2 inhibition, and the best chemotherapy backbone for neoadjuvant
chemotherapy still represent an issue for clinical practice. A literature-based meta-analysis …
chemotherapy still represent an issue for clinical practice. A literature-based meta-analysis …
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The …
P Vici, L Pizzuti, C Natoli, L Moscetti… - Breast cancer research …, 2014 - Springer
Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of
recurrence and has become the standard of care for human epidermal growth factor …
recurrence and has become the standard of care for human epidermal growth factor …
Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population
KB Baron, JR Brown, BL Heiss, J Marshall, N Tait… - Journal of Cardiac …, 2014 - Elsevier
Background Although it is known that trastuzumab causes cardiotoxicity, its extent and
reversibility are still in question. Earlier studies have not evaluated consecutive patients with …
reversibility are still in question. Earlier studies have not evaluated consecutive patients with …
Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery
HER2-positive breast cancer is a known risk factor for CNS metastases, and the use of
trastuzumab in the adjuvant setting does not prevent brain metastases. The purpose of this …
trastuzumab in the adjuvant setting does not prevent brain metastases. The purpose of this …
Risk factors and survival outcome in cerebral metastatic breast cancer
C Bachmann, S Schmidt, A Staebler, J Schittenhelm… - Medical Oncology, 2014 - Springer
The development of brain metastases (BM) of primary breast cancer patients leads to limited
survival. HER2-positive and triple-negative status are risk factors for the development of BM …
survival. HER2-positive and triple-negative status are risk factors for the development of BM …
[HTML][HTML] HER2 阳性型乳腺癌脑转移的研究进展
周霞， 杜向慧， 裘国勤 - 肿瘤防治研究, 2014 - zlfzyj.com
近年来曲妥珠单抗的广泛应用大大提高了HER2 (人表皮生长因子受体2) 过度表达乳腺癌患者的
生存率, 在全身性控制率提高和生存期延长的同时, 脑转移瘤的发病率也有所增加 …
生存率, 在全身性控制率提高和生存期延长的同时, 脑转移瘤的发病率也有所增加 …
TREATMENT OUTCOME IN WOMEN WITH OPERABLE HER2-POSITIVE BREAST CANCER: A SINGLE INSTITUTIONAL REPORT
JB Lin, CP Pi, DR Chen, ST Chen, TH Chang, LC Hung… - cancer - airitilibrary.com
Purpose: Women with HER-2 overexpressing breast carcinoma benefit from trastuzumab-
based systemic therapy despite the awareness of increasing risk of brain failure from this …
based systemic therapy despite the awareness of increasing risk of brain failure from this …
[PDF][PDF] Anti-Tumour Treatment
The role of the dual HER2 inhibition, and the best chemotherapy backbone for neoadjuvant
chemotherapy still represent an issue for clinical practice. A literature-based meta-analysis …
chemotherapy still represent an issue for clinical practice. A literature-based meta-analysis …